Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2015

01-04-2015 | review

Is dosing in oncology gender-sensitive?

Author: Christine Marosi, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2015

Login to get access

Abstract

Cancer is still the second cause of death in Europe and with the aging of populations, the number of cancer patients will further increase. For Austria, the gender-specific analysis of epidemiology and survival rates of cancer in the past 10 years show that there are significant differences between men and women that could at least partly been used for the implementation of future preventive and/or therapeutic actions. Gender-specific pharmacokinetic differences for medications with narrow therapeutic index as most of the drugs used in cancer therapy have been documented for more than a decade. It would be very helpful to develop instruments allowing individualized treatment planning taking into account the age, function of relevant organs, and gender of the patient than to adhere indefinitely to body surface area.
Literature
1.
Malvezzi M, et al. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–6.
2.
Bosetti C, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71.CrossRefPubMed
3.
4.
5.
Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14(9):2590–611.PubMed
6.
Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst. 1990;82(4):323–5.CrossRefPubMed
7.
Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19(2):171–7.CrossRefPubMed
8.
Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17(Chicago):863–71.CrossRef
9.
10.
Deeg HJ, et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transpl. 1995;15(3):461–8.
11.
Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41(5):329–42.CrossRefPubMed
12.
Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999;37(11):529–47.PubMed
13.
Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24(5):339–46.CrossRefPubMed
14.
Wasan KM, Kwong M. Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin. Pharmacol Toxicol. 1997;80(6):301–7.CrossRefPubMed
15.
Marazziti D, et al. Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr. 2013;18(3):118–27.CrossRefPubMed
16.
Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol. 2012;214:411–42.CrossRefPubMed
17.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.CrossRefPubMed
18.
Koren G, Nordeng H, MacLeod S. Gender differences in drug bioequivalence: time to rethink practices. Clin Pharmacol Ther. 2013;93(3):260–2.CrossRefPubMed
19.
Al-Khatib T, et al. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol. 2010;74(8):913–9.CrossRefPubMed
20.
Grunberg SM, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727–33.CrossRefPubMed
21.
Plunkett RJ, et al. Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg. 1999;90(6):1072–7.CrossRefPubMed
22.
Yates AJ, et al. Sex- and age-related differences in ceramide dihexosides of primary human brain tumors. Lipids. 1999;34(1):1–4.CrossRefPubMed
23.
Hodi FS, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008;5(9):557–61.CrossRefPubMed
24.
Jager U, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431–8.CrossRefPubMedCentralPubMed
25.
Cabanillas F, et al. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol. 2006;17(9):1424–7.CrossRefPubMed
26.
Tarella C, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814–24.CrossRefPubMed
27.
Jatoi A, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009;77(2):120–3.CrossRefPubMedCentralPubMed
28.
Kingham TP, Pachter HL. Colonic anastomotic leak: risk factors, diagnosis, and treatment. J Am Coll Surg. 2009;208(2):269–78.CrossRefPubMed
29.
Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol. 2008;20(1):104–11.CrossRefPubMed
30.
Lee JP, et al. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol. 2009;2:30.CrossRefPubMedCentralPubMed
31.
van der Veldt AA, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99(2):259–65.CrossRefPubMedCentralPubMed
32.
Rosell R, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.CrossRefPubMed
33.
Shiba S, et al. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res. 2014. doi:10.111/hep12297 [Epub ahead of print]
34.
Rapoport BL, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423–31.
Metadata
Title
Is dosing in oncology gender-sensitive?
Author
Christine Marosi, MD
Publication date
01-04-2015
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2015
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0178-0

Other articles of this Issue 1/2015

memo - Magazine of European Medical Oncology 1/2015 Go to the issue

short review

Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients

review

Radiotherapy for brain metastases: are we getting better?

short review

Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?

short review

A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma

short review

PET in lymphoma: who, when, how often, pitfalls?

short review

Optimal follow-up of endometrial cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits